Cell discohesion and multifocality of carcinoma in situ of the bladder: New insight from the adhesion molecule profile (e-Cadherin, Ep-CAM, and MUC1)

International Journal of Surgical Pathology

Volumn 17, Issue 2, 2009, Pages 99-106

  Patriarca, Carlo ^a   Colombo, Piergiuseppe ^b   Pio Taronna, Angelo ^c   Wesseling, Jelle ^d   Franchi, Giada ^b   Guddo, Francesca ^f   Naspro, Richard ^e   MacChi, Roberto Maria ^a   Giunta, Paolo ^a   Di Pasquale, Marcello ^a   Parente, Michele ^a   Arizzi, Carmelo ^a   Roncalli, Massimo ^b   Campo, Biagio ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^f Humanitas Gavazzeni Hospital   (Italy)

Author keywords

Bladder; Carcinoma in situ (CIS); Discohesion; E cadherin; MUC1; Urothelial cell carcinoma

Indexed keywords

ALPHA CATENIN; BETA CATENIN; DNA; EPITHELIAL CELL ADHESION MOLECULE; MUCIN 1; UVOMORULIN;

AGED; ARTICLE; BLADDER CARCINOMA; CARCINOMA IN SITU; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

AGED; ANTIGENS, NEOPLASM; CADHERINS; CARCINOMA IN SITU; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUCIN-1; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 62849126628     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/1066896908326918     Document Type: Article

References (32)

1. Murphy WM, Grignon DJ, Perlman EJ, eds. Carcinoma in situ. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Fascicle 1. Washington, DC: Armed Forces Institute of Pathology ; 2004: 276-280.
2. Witjes JA Bladder carcinoma in situ in 2003: state of the art. Eur Urol. 2004 ; 45: 142-146.
3. Shen SS, Lerner SP, Muezzinoglu B., Truong LD, Amiel G., Wheeler TM Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 ; 37: 726-734.
4. McKenney JK, Gomez JA, Desai S., Lee MW, Amin MB Morphological expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001 ; 25: 356-362.
5. Sun W., Herrera GA E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma and invasive transitional cell carcinoma. Hum Pathol. 2002 ; 33: 996-1000.
6. Shariat SF, Pahlavan S., Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 ; 57: 60-65.
7. Byrne RR, Shariat SF, Brown R., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol. 2001 ; 165: 1473-1479.
8. Sun W., Herrera GA E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol. 2004 ; 8: 17-22.
9. Bindels EMJ, Vermey M., van den Beemd R., Dinjens WNM, Van Der Kwast TH E-cadherin promotes intraepithelial expansion in an in vitro model of carcinoma in situ. Cancer Res. 2000 ; 60: 177-183.
10. Rieger-Christ KM, Cain JW, Braasch JW, et al. Expression of classic cadherin type 1 in urothelial neoplastic progression. Hum Pathol. 2001 ; 32: 18-23.
11. Clairotte A., Lascombe I., Fauconnet S., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gammacatenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006 ; 125: 119-126.
12. Bringuier PP, Giroldi LA, Umbas R., Shimazui T., Schalken J. Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. Int J Cancer. 1999 ; 83: 591-595.
13. Esteller M., Corn PG, Baylin SB, Herman JG A gene hypermethylation profile of human cancer. Cancer Res. 2001 ; 61: 3225-3229.
14. Wesseling J., van der Valk SW, Vos HL, Sonnenberg A., Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995 ; 129: 255-265.
15. Wesseling J., van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996 ; 7: 565-577.
16. Kohlgraf KG, Gawron AJ, Higashi M., et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 2003 ; 63: 5011-5020.
17. Rakha EA, Boyce RW, Abd El-Rehim D., et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005 ; 18: 1295-1304.
18. de Roos MA, van der Vegt B., Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumor characteristics and clinical outcome in "pure" ductal carcinoma in situ of the breast. Histopathology. 2007 ; 51: 227-238.
19. van der Vegt B., de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumor characteristics and clinical outcome in invasive ductal carcinoma of the breast. Histopathology. 2007 ; 51: 322-335.
20. Winter MJ, Nagtegaal ID, van Kneken JH, Litvinov SV The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003 ; 163: 2139-2148.
21. Lopez-Beltran A., Sauter G., Gasser T., et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. Lyon, France: IARC Press; 2004: 119-120.
22. Pu RT, Laitala LE, Clark DP Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006 ; 50: 499-506.
23. Dhawan D., Hamdy FC, Rehman I., et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol. 2006 ; 209: 336-343.
24. Horikawa Y., Sugano K., Shigyo M., et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high-grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol. 2003 ; 169: 1541-1545.
25. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002 ; 8: 464-470.
26. Cardillo RM, Castagna J., Memeo L., DeBernardis E., di Silverio F. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res. 2000 ; 19: 225-33.
27. Simms MS, Hughes OD, Limb M., Price RM, Bishop MC MUC1 mucin as a tumour marker in bladder cancer. BJU Int. 1999 ; 84: 350-352.
28. Nassar H., Pansare V., Zhang H., et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004 ; 16: 1-6.
29. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol. 2004 ; 171: 419-425.
30. Hilkens J., Ligtenberg MJ, Vos HL, Litvinov SV Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci. 1992 ; 17: 359-363.
31. Hoglund M. Bladder cancer, a two phase disease ? Semin Cancer Biol. 2007 ; 17: 225-232.
32. Fields AF, Keller AM, Schwartzberg L., et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study. Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology ; May 18-21, 2002 ; Orlando, FL. Abstract 508.